Alpha Tau Medical (NASDAQ:DRTS) CFO Raphi Levy Sells 17,500 Shares of Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 17,500 shares of Alpha Tau Medical stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $9.55, for a total value of $167,125.00. Following the completion of the transaction, the chief financial officer owned 130,180 shares in the company, valued at approximately $1,243,219. This represents a 11.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Price Performance

Shares of Alpha Tau Medical stock opened at $11.17 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.79 and a quick ratio of 7.79. Alpha Tau Medical Ltd. has a one year low of $2.87 and a one year high of $11.62. The business’s 50 day simple moving average is $9.33 and its two-hundred day simple moving average is $7.59. The stock has a market capitalization of $1.01 billion, a P/E ratio of -16.67 and a beta of 1.19.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Analysts forecast that Alpha Tau Medical Ltd. will post -0.67 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Apella Capital LLC bought a new stake in shares of Alpha Tau Medical during the fourth quarter valued at approximately $1,892,000. Daytona Street Capital LLC bought a new position in Alpha Tau Medical in the fourth quarter worth $749,000. Mariner LLC lifted its position in Alpha Tau Medical by 1.6% during the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after buying an additional 1,915 shares during the period. Millennium Management LLC lifted its position in Alpha Tau Medical by 185.7% during the fourth quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after buying an additional 70,081 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of Alpha Tau Medical during the 1st quarter valued at $286,000. Institutional investors own 2.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DRTS. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Alpha Tau Medical in a research note on Tuesday, June 2nd. Barclays boosted their target price on Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Piper Sandler raised their price target on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a report on Monday, April 20th. Finally, Citigroup boosted their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $12.60.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.